Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025

Reuters

2025/09/04

Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025

Immunic Inc., a biotechnology company specializing in the development of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, from September 24-26, 2025. During this conference, Immunic will present data on its lead asset, vidofludimus calcium (IMU-838), an orally available Nurr1 activator. The data will be shared through an oral presentation and four poster presentations, including a late-breaking poster. These presentations will cover analyses from the Phase 2 EMPhASIS Study of vidofludimus calcium in patients with Relapsing-Remitting Multiple Sclerosis. The presentation and posters will be made accessible on Immunic's website. Results from these studies will be presented during the specified conference sessions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2191562_en), on September 04, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2564822375"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564822375\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564822375?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 18:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564822375","market":"fut","top_or_hot":-1,"title":"Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Immunic Inc., a biotechnology company specializing in the development of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, from September 24-26, 2025. During this conference, Immunic will present data on its lead asset, vidofludimus calcium (IMU-838), an orally available Nurr1 activator. The data will be shared through an oral presentation and four poster presentations, including a late-breaking poster. These presentations will cover analyses from the Phase 2 EMPhASIS Study of vidofludimus calcium in patients with Relapsing-Remitting Multiple Sclerosis. The presentation and posters will be made accessible on Immunic's website. Results from these studies will be presented during the specified conference sessions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2191562_en), on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-04 18:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Immunic Inc., a biotechnology company specializing in the development of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, from September 24-26, 2025. During this conference, Immunic will present data on its lead asset, vidofludimus calcium (IMU-838), an orally available Nurr1 activator. The data will be shared through an oral presentation and four poster presentations, including a late-breaking poster. These presentations will cover analyses from the Phase 2 EMPhASIS Study of vidofludimus calcium in patients with Relapsing-Remitting Multiple Sclerosis. The presentation and posters will be made accessible on Immunic's website. Results from these studies will be presented during the specified conference sessions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2191562_en), on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMUX","symbol_name":"Immunic, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL7QLRpT:1","article_id":"2564822375","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564822375","pubTimestamp":1756981848,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immunic Inc., a biotechnology company specializing in the development of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis  in Barcelona, Spain, from September 24-26, 2025. During this conference, Immunic will present data on its lead asset, vidofludimus calcium , an orally available Nurr1 activator. The data will be shared through an oral presentation and four poster presentations, including a late-breaking poster. These presentations will cover analyses from the Phase 2 EMPhASIS Study of vidofludimus calcium in patients with Relapsing-Remitting Multiple Sclerosis. The presentation and posters will be made accessible on Immunic's website. Results from these studies will be presented during the specified conference sessions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMUX":"Immunic, Inc.","BK4139":"生物科技"},"translate_title":"Immunic Inc.在ECTRIMS 2025上宣布维多氟地莫斯钙治疗进行性多发性硬化症的新临床研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMUX":0.9},"content_text":"Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025\n    \n\n        Immunic Inc., a biotechnology company specializing in the development of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, from September 24-26, 2025. During this conference, Immunic will present data on its lead asset, vidofludimus calcium (IMU-838), an orally available Nurr1 activator. The data will be shared through an oral presentation and four poster presentations, including a late-breaking poster. These presentations will cover analyses from the Phase 2 EMPhASIS Study of vidofludimus calcium in patients with Relapsing-Remitting Multiple Sclerosis. The presentation and posters will be made accessible on Immunic's website. Results from these studies will be presented during the specified conference sessions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2191562_en), on September 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}